Novo Nordisk Bets on CagriSema and Oral Wegovy to Counter Pricing Headwinds and Analysts’ Caution
Novo Nordisk faces key test at ADA with CagriSema Phase 3 data; Wegovy oral prescriptions surge, European reimbursement…
Novo Nordisk’s Pipeline Ambitions Clash With Near-Term Revenue Fears as Analysts Flag 2027 Slowdow
Novo Nordisk stock up 26% but analyst warns of 3% revenue drop in 2027. Pipeline with Amycretin and…
Ørsted’s Strategic Asset Sales Drastically Reduce Debt Burden
Ørsted’s major asset sales slash debt, leading Barclays to upgrade its rating. Analysts forecast rising EBITDA as the…
Ørsted’s Strategic Asset Sales Drastically Reduce Debt Burden
Ørsted’s major asset sales slash debt, leading Barclays to upgrade its rating. Analysts forecast rising EBITDA as the…
Ørsted’s Financial Resilience Shines Amid Political Uncertainty
Ørsted posts strong 2023 results and raises divestment targets, while Denmark’s election puts state’s 50.1% stake up for…